FOSL2 expression in histologically diagnosed breast cancer: first immunohistochemical evidence from Cameroon.
8 affiliations
- 1Douala General Hospital, Douala, Cameroon.
- 2Faculty of Medicine and Pharmaceutical Sciences, University of Douala, Douala, Cameroon.
- 3Faculty of Health Sciences, University of Buea, Buea, Cameroon.
- 4Douala Gyneco-Obstetric and Pediatric Hospital, Douala, Cameroon. [email protected].
- 5National Cancer Control Committee of Cameroon, Yaoundé, Cameroon.
- 6Faculty of Medicine and Biomedical Sciences, University of Yaoundé I, Yaoundé, Cameroon.
- 7Faculty of Medicine and Pharmaceutical Sciences, University of Ebolowa, Ebolowa, Cameroon.
- 8Bridge Institute for Experimental Tumor Therapy, Cameroon Consortium for Translational Cancer Research, University Hospital Essen, Essen, Germany.
Abstract
Background
FOSL2 (Fra-2), a member of the AP-1 transcription factor family, has been implicated in breast cancer progression and metastasis in Asian and Western cohorts, but its expression has never been characterised in sub-Saharan African populations. We aimed to describe FOSL2 immunohistochemical expression in breast cancer patients managed at Douala General Hospital, Cameroon.Methods
We conducted a retrospective cross-sectional, descriptive and analytical study from November 2023 to September 2024. Formalin-fixed, paraffin-embedded specimens from women with histologically confirmed breast carcinoma were processed at Douala General Hospital and analysed by immunohistochemistry at Centre Pasteur du Cameroun. FOSL2 staining was assessed for subcellular localisation, intensity (0-3+), percentage of stained cells and H-score (0-300). Associations between FOSL2 expression (positivity, H-score) and clinicopathological variables were evaluated using Fisher's exact test and Mann-Whitney U test.Results
Fifty-five women (mean age 48.9 ± 13.8 years) were included. Invasive ductal carcinoma predominated (83.6%); 18 patients (32.7%) had metastatic disease at diagnosis. FOSL2 was expressed in 54/55 tumours (98.2%), with predominantly nuclear localisation (74.1%) and moderate intensity (61.8%). All metastatic tumours were FOSL2-positive (18/18), although positivity was similarly high among non-metastatic tumours (36/37, 97.3%). Median H-score was 20 (IQR 10-66) and did not differ significantly by metastatic status (p = 0.64), SBR grade (p = 0.21), histological type (p = 0.78), age group (p = 0.45) or prior neoadjuvant chemotherapy (p = 0.95). The near-universal positivity limited statistical power for detection of associations.Conclusions
To our knowledge, this is the first immunohistochemical study of FOSL2 expression in breast cancer in Cameroon. FOSL2 positivity was nearly universal (98.2%), although quantitative expression levels were generally low. Although all metastatic tumours expressed FOSL2, positivity was similarly high among non-metastatic tumours, precluding discrimination based on metastatic status. These findings justify further investigation of FOSL2 as a potential biomarker through larger studies with survival data and normal tissue controls.
Related
- Ovarian Stainology: Database of evidence-based immunohistochemical antigen expression in ovarian tumors
- PD-1 and PD-L1 Expression in Inflammatory Bowel Disease: A Paired Immunohistochemical Study
- Immunohistochemical Expression of M30, BCL-2, BAX, and Ki-67 in Pancreatic Ductal Adenocarcinoma: Association with Clinicopathological Features
- VEGF-A Immunohistochemical Expression Across Appendiceal Epithelial Lesions: A Retrospective Exploratory Study
- Prognostic Significance of p53 Immunohistochemical Expression and Molecular Characterization of TP53 Variants in Triple-Negative Breast Cancer After Neoadjuvant Chemotherapy
BibTeX
@article{noa2026fosl2,
title = {{FOSL2 expression in histologically diagnosed breast cancer: first immunohistochemical evidence from Cameroon.}},
author = {Sidonie Agnès Ananga Noa and Esther Dina Bell and Dominique Anaba and Clément Parfait Ndengue and Berthe Mapoko and Madeleine Ekopmou Ngangue and Paul Jean Adrien Atangana and Smiths Sengkwawoh Lueong},
journal = {BMC cancer},
year = {2026},
month = aug,
doi = {10.1186/s12885-026-16682-z},
url = {https://europepmc.org/article/MED/43009837},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - FOSL2 expression in histologically diagnosed breast cancer: first immunohistochemical evidence from Cameroon.
AU - Sidonie Agnès Ananga Noa
AU - Esther Dina Bell
AU - Dominique Anaba
AU - Clément Parfait Ndengue
AU - Berthe Mapoko
AU - Madeleine Ekopmou Ngangue
AU - Paul Jean Adrien Atangana
AU - Smiths Sengkwawoh Lueong
PY - 2026
DA - 2026/08/12
JO - BMC cancer
DO - 10.1186/s12885-026-16682-z
UR - https://europepmc.org/article/MED/43009837
AB - Background FOSL2 (Fra-2), a member of the AP-1 transcription factor family, has been implicated in breast cancer progression and metastasis in Asian and Western cohorts, but its expression has never been characterised in sub-Saharan African populations. We aimed to describe FOSL2 immunohistochemical expression in breast cancer patients managed at Douala General Hospital, Cameroon.Methods We conducted a retrospective cross-sectional, descriptive and analytical study from November 2023 to September 2024. Formalin-fixed, paraffin-embedded specimens from women with histologically confirmed breast carcinoma were processed at Douala General Hospital and analysed by immunohistochemistry at Centre Pasteur du Cameroun. FOSL2 staining was assessed for subcellular localisation, intensity (0-3+), percentage of stained cells and H-score (0-300). Associations between FOSL2 expression (positivity, H-score) and clinicopathological variables were evaluated using Fisher's exact test and Mann-Whitney U test.Results Fifty-five women (mean age 48.9 ± 13.8 years) were included. Invasive ductal carcinoma predominated (83.6%); 18 patients (32.7%) had metastatic disease at diagnosis. FOSL2 was expressed in 54/55 tumours (98.2%), with predominantly nuclear localisation (74.1%) and moderate intensity (61.8%). All metastatic tumours were FOSL2-positive (18/18), although positivity was similarly high among non-metastatic tumours (36/37, 97.3%). Median H-score was 20 (IQR 10-66) and did not differ significantly by metastatic status (p = 0.64), SBR grade (p = 0.21), histological type (p = 0.78), age group (p = 0.45) or prior neoadjuvant chemotherapy (p = 0.95). The near-universal positivity limited statistical power for detection of associations.Conclusions To our knowledge, this is the first immunohistochemical study of FOSL2 expression in breast cancer in Cameroon. FOSL2 positivity was nearly universal (98.2%), although quantitative expression levels were generally low. Although all metastatic tumours expressed FOSL2, positivity was similarly high among non-metastatic tumours, precluding discrimination based on metastatic status. These findings justify further investigation of FOSL2 as a potential biomarker through larger studies with survival data and normal tissue controls.
SN - 1471-2407
ER -